(Yicai Global) Dec. 28 -- Chinese mainland users of Shanghai Fosun Pharmaceutical Group’s app and WeChat mini program can register to receive BioNTech’s mRNA Covid-19 vaccine in Hong Kong.

After a mainland resident’s application has been approved by Fosun Pharma, they can travel to Hong Kong at their own expense and get a Comirnaty jab as a booster shot, the firm said in a statement yesterday.

Comirnaty is the only omicron variant-adapted vaccine available as a booster for people aged over 12 years that was granted a certificate of registration by the Health Bureau of the Special Administrative Region.

Shanghai-based Fosun Pharma won the exclusive China rights to develop and commercialize BioNTech’s mRNA vaccine in March 2020.

The announcement came a day after China said it will scrap quarantine requirements for international arrivals from Jan. 8 after downgrading the management level for Covid-19 to Category B from Category A, the highest.

Editors: Liao Shumin, Futura Costaglione